Oncolytics Biotech® Inc. (NASDAQ: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed ...
The partnership will accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO ...
Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the ...
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable ...
DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years ...
"When I'm on the court, it's for everybody else. And that makes it so easy," said Ogbechie, a 6-foot-3 middle blocker.
No weapons of mass destruction were deployed. There were no fatalities. The soldiers didn’t carry firearms or wear uniforms; ...
Sitting across 1000 square metres just 11km out of the Melbourne CBD is the world’s first nano-manufacturing plant. The ...
Greenlight Capital funds returned -3.6% in Q3 2025, net of fees and expenses, compared to 8.1% for the S&P 500 index, ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of ...
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback